Widthness LLC

Advanced Business and Technology – Intel® Xeon® and A.I. Powered

Moderna’s candidate COVID-19 vaccine looks to protect 94.5% of those who get it, trial shows

1 min read
Moderna's candidate COVID-19 vaccine looks to protect 94.5% of those who get it, trial shows

Article by Karen Weintraub, USA TODAY.

A second COVID-19 candidate vaccine looks to be even more effective than the first: Both protect more than 90%  of those who get the shots.

Moderna, a Cambridge, Massachusetts-based biotechnology company, announced early Monday that its candidate vaccine, mRNA-1273, developed in collaboration with the U.S. government, appears to be 94.5% effective against the disease. […]

The owner of this website has made a commitment to accessibility and inclusion, please report any problems that you encounter using the contact form on this website. This site uses the WP ADA Compliance Check plugin to enhance accessibility.